Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.60 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | TAOK3 | Q9H2K8 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393199 | 1.00 | MTNR1A (0.60) | MTNR1AMTNR1BTAOK1GRM5TAOK3 | |
| SCHEMBL3393202 | 1.00 | MTNR1A (0.60) | MTNR1AMTNR1BTAOK1GRM5TAOK3 | |
| SCHEMBL9731843 | 0.88 | MTNR1A (0.67) | MTNR1AMTNR1BTAOK1TAOK3NPC1 | |
| SCHEMBL3392060 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BTAOK1GRM5TAOK3 | |
| SCHEMBL30823644 | 0.83 | MEN1 (0.68) | MTNR1AMTNR1BTAOK1TAOK3NPC1 | |
| SCHEMBL22289338 | 0.83 | MEN1 (0.68) | MTNR1AMTNR1BTAOK1TAOK3NPC1 | |
| SCHEMBL5522805 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BTAOK1GRM5TAOK3 | |
| SCHEMBL3390898 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BTAOK1GRM5TAOK3 | |
| SCHEMBL1544549 | 0.78 | L3MBTL1 (0.61) | GRM5NPC1RAB9ASMN1; SMN2CYP46A1 | |
| SCHEMBL3394258 | 0.78 | MTNR1A (0.60) | MTNR1AMTNR1BTAOK1GRM5TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370530-B1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | MTNR1A 604/4885MTNR1B 448/4885TAOK1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.